
BRIM — Investor Relations & Filings
BRIM Biotechnology, Inc. specializes in the application of translational science to develop innovative therapies for unmet medical needs. The company utilizes its proprietary Pigment Epithelium-Derived Factor (PEDF) Derived Short Peptide (PDSP) technology platform, which leverages neurotrophic properties to stimulate cell proliferation, wound healing, and tissue regeneration. Its research pipeline primarily targets ophthalmology and degenerative conditions, featuring lead candidates such as BRM421 for dry eye syndrome, BRM424 for neurotrophic keratitis, and BRM521 for osteoarthritis. Operating through an integrated model, the company advances drug candidates to the proof-of-concept stage before pursuing strategic licensing and partnerships for late-stage development. BRIM also incorporates precision medicine and bioinformatics to explore combination therapies and enhance therapeutic outcomes.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 115年年報及股東會資料 — 2026_6885_20260612FE5.pdf | 2026-05-12 | English | |
| 115年年報及股東會資料 — 2026_6885_20260612FE2.pdf | 2026-05-12 | English | |
| 115年年報及股東會資料 — 2026_6885_20260612FE1.pdf | 2026-05-12 | English | |
| 115年年報及股東會資料 — 2026_6885_20260612F02.pdf | 2026-05-12 | Chinese | |
| 115年年報及股東會資料 — 2026_6885_20260612F01.pdf | 2026-05-12 | Chinese | |
| 115年年報及股東會資料 — 2026_6885_20260612F13.pdf | 2026-05-12 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45772690 | 115年年報及股東會資料 — 2026_6885_20260612FE5.pdf | 2026-05-12 | English | ||
| 45772689 | 115年年報及股東會資料 — 2026_6885_20260612FE2.pdf | 2026-05-12 | English | ||
| 45772688 | 115年年報及股東會資料 — 2026_6885_20260612FE1.pdf | 2026-05-12 | English | ||
| 45772687 | 115年年報及股東會資料 — 2026_6885_20260612F02.pdf | 2026-05-12 | Chinese | ||
| 45772686 | 115年年報及股東會資料 — 2026_6885_20260612F01.pdf | 2026-05-12 | Chinese | ||
| 45772685 | 115年年報及股東會資料 — 2026_6885_20260612F13.pdf | 2026-05-12 | Chinese | ||
| 45746302 | 115年第1季權益變動表 | 2026-05-11 | Chinese | ||
| 45746232 | 115年第1季現金流量表 | 2026-05-11 | Chinese | ||
| 45741513 | 115年第1季綜合損益表 | 2026-05-11 | Chinese | ||
| 45741321 | 115年第1季資產負債表 | 2026-05-11 | Chinese | ||
| 45544696 | 115年第1季財務報告書 — 202601_6885_AI1.pdf | 2026-05-11 | Chinese | ||
| 33964967 | 115年4月變更登記 | 2026-04-10 | Chinese | ||
| 33964970 | 公司基本資料 | 2026-04-10 | Chinese | ||
| 33902475 | 公告本公司限制員工權利新股收回註銷完成變更登記 | 2026-04-09 | Chinese | ||
| 33893046 | 115年04月僑外投資持股 | 2026-04-09 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
IMV Inc.
Pioneering novel immunotherapies using the proprietary DPX®…
|
IMV | CA | Professional, scientific and te… |
|
INBIOGEN CO.,Ltd
A life sciences firm offering bioinformatics and data minin…
|
101140 | KR | Professional, scientific and te… |
|
Incannex Healthcare Inc.
A clinical-stage biopharma firm developing cannabinoid and …
|
IXHL | US | Professional, scientific and te… |
|
Indaptus Therapeutics, Inc.
Develops bacterial-based immunotherapies for cancer and vir…
|
INDP | US | Professional, scientific and te… |
|
InflaRx N.V.
Clinical-stage biopharmaceutical firm developing C5a/C5aR p…
|
IFRX | NL | Professional, scientific and te… |
|
Inhalation Sciences Sweden AB
Develops lab instruments and provides research for preclini…
|
ISAB | SE | Professional, scientific and te… |
|
Initiator Pharma A/S
Clinical-stage company developing drugs for central and per…
|
INIT | DK | Professional, scientific and te… |
|
Inmolecule Nanotech, S.A.
Develops nanoparticles from plant compounds for biomedical …
|
MLINA | ES | Professional, scientific and te… |
|
InNexus Biotechnology Inc.
Develops enhanced monoclonal antibodies and diagnostics usi…
|
IXSBF | CA | Professional, scientific and te… |
|
Inotiv, Inc.
A CRO providing nonclinical drug development services and r…
|
NOTV | US | Professional, scientific and te… |
BRIM via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52650/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52650 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52650 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52650 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52650}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for BRIM (id: 52650)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.